Abstract
Feverfew (Tanacetum parthenium) has had a traditional reputation for treating fever, headache, and women's ailments. Only in the 1970s did feverfew gain popularity as a migraine prophylactic. The effectiveness of feverfew in reducing the incidence and severity of migraine headache attacks, along with alleviating associated nausea and vomiting, has been established in randomized controlled clinical trials, primarily using whole feverfew leaf, whereas more recently a supercritical carbon dioxide fluid extract has been shown successful, although only in a small subset of subjects who experienced at least four migraine attacks monthly. The demise of the formerly widely touted anti-migraine mechanism involving the sesquiterpene lactone parthenolide has focused attention on other feverfew constituents as potential candidates for the mantle of active principle.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
